InMed receives Nasdaq deficiency notice on equity requirement

InMed Pharmaceuticals received a Nasdaq deficiency notice after reporting shareholders' equity of $1.08 million, below the $2.5 million minimum required for continued Nasdaq Capital Market listing. The shortfall reflects merger-related costs, the BayMedica wind-down, higher G&A expenses, intangible-asset impairments and continued operating losses. InMed has 45 days to submit a compliance plan and expects its planned Q4 2026 merger with Mentari Therapeutics, including approximately $490 million in pre-closing financing, to restore compliance; failure could ultimately result in delisting.

Analysis

INM is now effectively a binary merger-financing security rather than a standalone biotech valuation. The equity deficit itself is not the central economic issue; the key question is whether the stated financing is fully committed, funded at close, and sufficient after redemptions, transaction costs, and the combined entity's cash burn. A compliance plan can preserve listing optionality over the next 1-6 months, but it does not eliminate the risk of a failed vote, financing-condition breach, or materially dilutive restructuring before the targeted closing.

The near-100% rerating since the transaction announcement likely embeds substantial closing probability despite limited standalone balance-sheet support. In comparable reverse-merger situations, a listing notice can widen the discount to implied transaction value because arbitrage capital demands compensation for timing uncertainty and post-close dilution. The second-order beneficiary is NDAQ only marginally: this is immaterial to exchange economics, though a broader increase in small-cap biotech listing deficiencies would be a weak indicator of financing stress in the microcap healthcare ecosystem.

Consensus may overfocus on the prospective gross-proceeds figure. Gross proceeds are not pro forma shareholders' equity, and the conversion terms of prior notes, earn-outs, preferred securities, warrants, and merger exchange ratio determine whether current INM holders retain meaningful upside. The falsifier for a cautious view is a definitive proxy detailing a clean capitalization table, binding financing with limited outs, and pro forma cash runway of at least 18 months; absent that, upside should be treated as event-driven speculation rather than a fundamental recovery.

Key Decisions for Investors

• Avoid initiating a directional long in INM before the merger proxy/S-4 equivalent discloses the exchange ratio, fully diluted share count, financing terms, and post-close cash runway. Use the filing as the decision point over the next 30-60 days, not the Nasdaq compliance-plan deadline.
• For event-driven mandates only, consider a small INM long after definitive financing documentation, sized as a binary position and capped at 25-50 bps of NAV. Target requires a discounted entry after listing-notice volatility; exit immediately if shareholder approval is delayed, financing is resized, or pro forma runway is below 12 months.
• Do not use NDAQ as a sympathy short or long; the issuer-specific notice has no measurable earnings sensitivity for the exchange operator.
• Set alerts for: Nasdaq acceptance/rejection of the compliance plan, merger proxy filing, financing amendments, and any revised closing date. A delay beyond Q4 2026 or material increase in fully diluted shares should be treated as thesis failure for a merger-arbitrage long.